Fmr LLC Decreases Stock Position in Zoetis Inc. (NYSE:ZTS)

Fmr LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 5.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,344,239 shares of the company’s stock after selling 231,939 shares during the period. Fmr LLC owned approximately 0.96% of Zoetis worth $848,777,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in ZTS. Darwin Wealth Management LLC purchased a new position in Zoetis during the 3rd quarter valued at approximately $31,000. First Personal Financial Services bought a new position in Zoetis during the third quarter valued at $33,000. Capital Performance Advisors LLP purchased a new position in Zoetis in the third quarter worth about $33,000. Quarry LP raised its holdings in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares during the period. Finally, LRI Investments LLC bought a new position in Zoetis during the first quarter valued at $43,000. 92.80% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus boosted their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. raised their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, BTIG Research upped their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Trading Up 0.6 %

Shares of NYSE ZTS opened at $176.74 on Thursday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The firm has a market cap of $79.74 billion, a PE ratio of 33.22, a price-to-earnings-growth ratio of 2.70 and a beta of 0.90. The business has a fifty day simple moving average of $184.51 and a two-hundred day simple moving average of $180.81. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the company posted $1.36 earnings per share. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. Analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. Zoetis’s dividend payout ratio is presently 32.52%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.